[F]FMISO PET/CT imaging of hypoxia as a non-invasive biomarker of disease progression and therapy efficacy in a preclinical model of pulmonary fibrosis: comparison with the [F]FDG PET/CT approach.
Fiche publication
Date publication
février 2021
Journal
European journal of nuclear medicine and molecular imaging
Auteurs
Membres identifiés du Cancéropôle Est :
Dr COLLIN Bertrand, Pr COCHET Alexandre, Dr BELLAYE Pierre-Simon, Pr BONNIAUD Philippe
Tous les auteurs :
Tanguy J, Goirand F, Bouchard A, Frenay J, Moreau M, Mothes C, Oudot A, Helbling A, Guillemin M, Bonniaud P, Cochet A, Collin B, Bellaye PS
Lien Pubmed
Résumé
Idiopathic pulmonary fibrosis (IPF) is a progressive disease with poor outcome and limited therapeutic options. Imaging of IPF is limited to high-resolution computed tomography (HRCT) which is often not sufficient for a definite diagnosis and has a limited impact on therapeutic decision and patient management. Hypoxia of the lung is a significant feature of IPF but its role on disease progression remains elusive. Thus, the aim of our study was to evaluate hypoxia imaging with [F]FMISO as a predictive biomarker of disease progression and therapy efficacy in preclinical models of lung fibrosis in comparison with [F]FDG.
Mots clés
Hypoxia, Lung fibrosis, PET/CT, [18F]FDG, [18F]FMISO
Référence
Eur J Nucl Med Mol Imaging. 2021 Feb 13;: